PTGS2 and Kaposi's sarcoma: The activation of COX-2 by KSHV infection [31–33,35,51], and the involvement in vGPCR angiogenesis and tumorigenesis, as shown in this study, suggest that COX-2 could be a therapeutic target in KS.